Grimes & Company Inc. Acquires New Position in VanEck Pharmaceutical ETF (NASDAQ:PPH)

Grimes & Company Inc. bought a new position in VanEck Pharmaceutical ETF (NASDAQ:PPH) in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 3,589 shares of the company’s stock, valued at approximately $310,000. Grimes & Company Inc. owned about 0.06% of VanEck Pharmaceutical ETF at the end of the most recent quarter.

Several other institutional investors and hedge funds have also added to or reduced their stakes in the stock. FMR LLC raised its holdings in VanEck Pharmaceutical ETF by 12.5% in the 3rd quarter. FMR LLC now owns 1,905 shares of the company’s stock valued at $181,000 after buying an additional 212 shares during the last quarter. Edge Financial Advisors LLC acquired a new position in shares of VanEck Pharmaceutical ETF during the 3rd quarter valued at $263,000. Harbour Investments Inc. boosted its position in shares of VanEck Pharmaceutical ETF by 16.6% during the 3rd quarter. Harbour Investments Inc. now owns 3,425 shares of the company’s stock worth $325,000 after purchasing an additional 488 shares in the last quarter. Townsquare Capital LLC boosted its holdings in VanEck Pharmaceutical ETF by 3.8% in the third quarter. Townsquare Capital LLC now owns 3,519 shares of the company’s stock worth $334,000 after acquiring an additional 130 shares in the last quarter. Finally, Assetmark Inc. grew its position in VanEck Pharmaceutical ETF by 5.8% in the 3rd quarter. Assetmark Inc. now owns 6,491 shares of the company’s stock valued at $617,000 after purchasing an additional 354 shares during the period.

VanEck Pharmaceutical ETF Price Performance

NASDAQ:PPH opened at $87.71 on Monday. The firm has a 50-day moving average of $87.64 and a 200-day moving average of $91.96. The company has a market cap of $573.62 million, a PE ratio of 21.04 and a beta of 0.72. VanEck Pharmaceutical ETF has a one year low of $83.74 and a one year high of $99.51.

VanEck Pharmaceutical ETF Increases Dividend

The company also recently announced a dividend, which was paid on Monday, December 30th. Stockholders of record on Friday, December 27th were paid a $0.411 dividend. This is a positive change from VanEck Pharmaceutical ETF’s previous dividend of $0.36. The ex-dividend date was Friday, December 27th.

VanEck Pharmaceutical ETF Profile

The VanEck Pharmaceutical ETF (PPH) is an exchange-traded fund that is based on the MVIS US Listed Pharmaceutical 25 index, a market-cap-weighted index of 25 of the largest global pharmaceutical firms. PPH was launched on Feb 1, 2000 and is managed by VanEck.